Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

Early results from Wave's ongoing DMD Phase II trial saw a decline in muscle necrosis and inflammation in the trial ...

A violent armed robber who turned to drug dealing after being released from prison was found with a fully-loaded working ...

The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.